Orchid Pharma Ltd

Orchid Pharma Forms Orchid AMS | NDTV Profit (youtube.com)
Interview with the CEO, Rajnish Rohtagi.

• Expects 250-300 Cr in the new division in next 2-3 years. This roughly provides us a 10-12k crores addressable market (injectables not oral: ICU, hospital wards), and we are targeting a 3000 cr market, this translates to a 10% market share.
• Sales to begin in next 2-3 Months in this division.
• The division will primarily focus on injectable antibiotics used in hospitals, avoiding the crowded oral tablet market.
• Sales will come from a wide range of Antibiotics.
• The division plans to launch over 30 antibiotic molecules within the next 60 days.
• Cefiderocol will be launched within the next 1 year – will be the only distributor for it with in India & also be manufacturer/supplier to the sponsor, GARDP.
• Antibiotics is a hypercompetitive space, but Orchid wants to differentiate itself through a wide product range and addressing AMR in collaboration with hospitals.